CoChat
Sign Up
Cited by 118

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems

Gyanani, Vijay, Haley, Jeffrey C., Goswami, Roshan·2021·Pharmaceuticals
DOI 10.3390/ph14090835PMC PMC8466509
Open this paper in CoChat — free account

Abstract

According to a 2020 World Health Organization report (Globocan 2020), cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The aim of anticancer therapy is to specifically inhibit the growth of cancer cells while sparing normal dividing cells. Conventional chemotherapy, radiotherapy and surgical treatments have often been plagued by the frequency and severity of side effects as well as severe patient discomfort. Cancer targeting by drug delivery systems, owing to their selective targeting, efficacy, biocompatibility and high drug payload, provides an attractive alternative treatment; however, there are technical, therapeutic, manufacturing and clinical barriers that limit their use. This article provides a brief review of the challenges of conventional anticancer therapies and anticancer drug targeting with a special focus on liposomal drug delivery systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph14090835

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MDR exhibited by overexpression of Pgp transporter proteins leading to efflux of drug from cancer cells.
Figure 1 MDR exhibited by overexpression of Pgp transporter proteins leading to efflux of drug from cancer cells.CC BY · PubMed Central
Figure 2 Limitations of active and passive targeting.
Figure 2 Limitations of active and passive targeting.CC BY · PubMed Central
Figure 3 ‘Enhanced Permeation and Retention’ effect exhibiting enhanced permeability of liposomes in inter-tumoral space.
Figure 3 ‘Enhanced Permeation and Retention’ effect exhibiting enhanced permeability of liposomes in inter-tumoral space.CC BY · PubMed Central
Figure 4 Doxil coated with Polyethylene Glycol.
Figure 4 Doxil coated with Polyethylene Glycol.CC BY · PubMed Central
Figure 5 Drug release from liposomes by photo-isomerization of lipids.
Figure 5 Drug release from liposomes by photo-isomerization of lipids.CC BY · PubMed Central
Figure 6 Drug release from liposomes by photo-cleavage of lipids.
Figure 6 Drug release from liposomes by photo-cleavage of lipids.CC BY · PubMed Central
Figure 7 Drug release from liposomes by photo-polymerization of lipids.
Figure 7 Drug release from liposomes by photo-polymerization of lipids.CC BY · PubMed Central
Figure 8 Enhanced liposomal extravasation and drug release at tumor site upon application of heat.
Figure 8 Enhanced liposomal extravasation and drug release at tumor site upon application of heat.CC BY · PubMed Central
Figure 9 Traditional thermosensitive liposomes showing gel to fluid phase transition upon application of heat.
Figure 9 Traditional thermosensitive liposomes showing gel to fluid phase transition upon application of heat.CC BY · PubMed Central
Figure 10 Traditional thermosensitive drug loaded liposomes showing formation of micellar pockets upon application of heat.
Figure 10 Traditional thermosensitive drug loaded liposomes showing formation of micellar pockets upon application of heat.CC BY · PubMed Central
Figure 11 Iron oxide nanoparticles incorporated in lipid membrane.
Figure 11 Iron oxide nanoparticles incorporated in lipid membrane.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 125

  1. Gyanani, V. (2013). Turning Stealth Liposomes into Cationic Liposomes for Anticancer Drug Delivery. [Ph.D. Thesis, University of the Pacific].
  2. Allen, 2002, Ligand-targeted therapeutics in anticancer therapy, Nat. Rev. Cancer, 2, 750, 10.1038/nrc903 · DOI
  3. Yao, 2007, Cisplatin nephrotoxicity: A review, Am. J. Med. Sci., 334, 115, 10.1097/MAJ.0b013e31812dfe1e · DOI
  4. Pfeffer, 2009, Current concepts of anthracycline cardiotoxicity: Pathogenesis, diagnosis and prevention, Br. J. Cardiol., 16, 85
  5. Partridge, 2001, Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer, J. Natl. Cancer Inst. Monogr., 30, 135, 10.1093/oxfordjournals.jncimonographs.a003451 · DOI
  6. Fabbrocini, 2012, Chemotherapy and skin reactions, J. Exp. Clin. Cancer Res., 31, 50, 10.1186/1756-9966-31-50 · DOI
  7. Bentzen, 2006, Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology, Nat. Rev. Cancer, 6, 702, 10.1038/nrc1950 · DOI
  8. Bosslet, 1998, Elucidation of the mechanism enabling tumor selective prodrug monotherapy, Cancer Res., 58, 1195
  9. Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K.F., Rait, A., and Chang, E.H. (2012). Results of a Phase I Trial of SGT-53: A Systemically Administered, Tumor-Targeting Immunoliposome Nanocomplex Incorporating a Plasmid Encoding wtp53. Clin. Gene Cell Ther. Oral Abstr. Sess., 20. · DOI
  10. Pirollo, 2016, Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study, Mol. Ther., 24, 1697, 10.1038/mt.2016.135 · DOI
  11. Kim, 2021, Liposomes: Biomedical Applications, Chonnam. Med. J., 57, 27, 10.4068/cmj.2021.57.1.27 · DOI
  12. Moles, 2019, A potent targeted cancer nanotherapeutic, Nat. Biomed. Eng., 3, 248, 10.1038/s41551-019-0390-7 · DOI
  13. Wang, 2018, Clinical translation of immunoliposomes for cancer therapy: Recent perspectives, Expert Opin. Drug Deliv., 15, 893, 10.1080/17425247.2018.1517747 · DOI
  14. Yan, 2020, Updates on the use of liposomes for active tumor targeting in cancer therapy, Nanomedicine, 15, 303, 10.2217/nnm-2019-0308 · DOI
  15. Paranthaman, S., Goravinahalli Shivananjegowda, M., Mahadev, M., Moin, A., Hagalavadi Nanjappa, S., Nanjaiyah, N., Chidambaram, S.B., and Gowda, D.V. (2020). Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management. Pharmaceutics, 12. · DOI
  16. Miller, K., Cortes, J., Hurvitz, S.A., Krop, I.E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J.G., Wickham, T.J., and Molnar, I. (2016). HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer, 16. · DOI
  17. Gargett, 2018, Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma, Cancer Immunol. Immunother., 67, 1461, 10.1007/s00262-018-2207-z · DOI
  18. Liu, 2020, Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy, Mol. Ther.-Methods Clin. Dev., 18, 751, 10.1016/j.omtm.2020.07.015 · DOI
  19. Zhang, 2016, A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers, Mol. Ther., 24, 1484, 10.1038/mt.2016.118 · DOI
  20. Song, 2017, Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG(2000)-transferrin in treatment of brain glioma, Eur. J. Pharm. Sci., 96, 129, 10.1016/j.ejps.2016.09.024 · DOI
  21. Chiani, 2018, Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin, Artif. Cells Nanomed. Biotechnol., 46, 757, 10.1080/21691401.2017.1337029 · DOI
  22. Capone, 2017, Formulation of liposomes functionalized with Lotus lectin and effective in targeting highly proliferative cells, Biochim Biophys. Acta Gen. Subj., 1861, 860, 10.1016/j.bbagen.2017.01.015 · DOI
  23. Cristiano, 2017, Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells, Colloids Surf. B Biointerfaces, 150, 408, 10.1016/j.colsurfb.2016.10.052 · DOI
  24. Grace, 2017, Pharmacokinetics and therapeutic efficiency of a novel cationic liposome nano-formulated all trans retinoic acid in lung cancer mice model, J. Drug Deliv. Sci. Technol., 39, 223, 10.1016/j.jddst.2017.04.005 · DOI
  25. Lancet, 2018, CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia, J. Clin. Oncol., 36, 2684, 10.1200/JCO.2017.77.6112 · DOI
  26. Pelzer, 2017, Quality-adjusted survival with combination nal-IRI+5-FU/LV vs. 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis, Br. J. Cancer, 116, 1247, 10.1038/bjc.2017.67 · DOI · Paper page
  27. Tran, 2017, Cancer nanomedicine: A review of recent success in drug delivery, Clin. Transl. Med., 6, 44, 10.1186/s40169-017-0175-0 · DOI · Paper page
  28. Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9. · DOI
  29. Lamichhane, N., Udayakumar, T.S., D’Souza, W.D., Simone, C.B., Raghavan, S.R., Polf, J., and Mahmood, J. (2018). Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery. Molecules, 23. · DOI
  30. Bozzuto, 2015, Liposomes as nanomedical devices, Int. J. Nanomed., 10, 975, 10.2147/IJN.S68861 · DOI
  31. Ghosh, 2019, Liposomal formulations of photosensitizers, Biomaterials, 218, 119341, 10.1016/j.biomaterials.2019.119341 · DOI
  32. Lombardo, D., Calandra, P., Barreca, D., Magazù, S., and Kiselev, M.A. (2016). Soft Interaction in Liposome Nanocarriers for Therapeutic Drug Delivery. Nanomaterials, 6. · DOI
  33. Hong, 2020, Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumors, Br. J. Cancer, 122, 1630, 10.1038/s41416-020-0802-1 · DOI
  34. Lin, 2017, Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly, Theranostics, 7, 4805, 10.7150/thno.20771 · DOI
  35. Shi, 2017, Cancer nanomedicine: Progress, challenges and opportunities, Nat. Rev. Cancer, 17, 20, 10.1038/nrc.2016.108 · DOI · Paper page
  36. Gabizon, 2020, Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside, Adv. Drug Deliv. Rev., 154–155, 13, 10.1016/j.addr.2020.07.027 · DOI
  37. (2021, August 13). Available online: http://web.archive.org/web/20210813024839/https://www.globenewswire.com/news-release/2020/01/23/1974347/0/en/LipoMedix-Announces-Publication-of-Positive-Phase-1-Data-for-Promitil-PL-MLP-in-Research-Journal-Investigational-New-Drugs.html.
  38. (2021, August 13). Available online: https://web.archive.org/web/20210813030047/https://adisinsight.springer.com/drugs/800018766.
  39. Chien, 2020, Therapeutic Efficacy Evaluation of Pegylated Liposome Encapsulated with Vinorelbine Plus (111) in Repeated Treatments in Human Colorectal Carcinoma with Multimodalities of Molecular Imaging, Cancer Genom. Proteom., 17, 61, 10.21873/cgp.20168 · DOI
  40. Greil, 2018, A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc(™)) in patients with locally advanced or metastatic cancer, Cancer Chemother. Pharmacol., 82, 695, 10.1007/s00280-018-3654-0 · DOI
  41. Bolger, 2017, Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance, Anticancer Res., 37, 3483
  42. (2021, August 12). Available online: https://web.archive.org/web/20210813032817/https://apnews.com/press-release/pr-businesswire/eb9457dc9500491e918b53fdeeb75494.
  43. Graziani, 2017, Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma, Med. Oncol., 34, 151, 10.1007/s12032-017-1009-z · DOI
  44. Occhiutto, 2016, Paclitaxel Associated with Lipid Nanoparticles as a New Antiscarring Agent in Experimental Glaucoma Surgery, Investig. Ophthalmol. Vis. Sci., 57, 971, 10.1167/iovs.15-18671 · DOI
  45. Gomes, 2018, Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy with Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles, J. Cardiovasc. Pharmacol. Ther., 23, 561, 10.1177/1074248418778836 · DOI
  46. Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387 · DOI · Paper page
  47. Adams, 2001, High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules, Cancer Res., 61, 4750
  48. Tolcher, 1999, Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer, J. Clin. Oncol., 17, 478, 10.1200/JCO.1999.17.2.478 · DOI
  49. Kamoun, 2019, Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models, Nat. Biomed. Eng., 3, 264, 10.1038/s41551-019-0385-4 · DOI
  50. Matusewicz, 2019, EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers, Int. J. Pharm., 569, 118605, 10.1016/j.ijpharm.2019.118605 · DOI
  51. Khayrani, A.C., Mahmud, H., Oo, A.K.K., Zahra, M.H., Oze, M., Du, J., Alam, M.J., Afify, S.M., Quora, H.A.A., and Shigehiro, T. (2019). Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel. Int. J. Mol. Sci., 20. · DOI
  52. Hua, 2019, Synthesis and in vitro characterization of oxytocin receptor targeted PEGylated immunoliposomes for drug delivery to the uterus, J. Liposome Res., 29, 357, 10.1080/08982104.2018.1556293 · DOI
  53. Takahara, 2020, Synthetic Strategies for Artificial Lipidation of Functional Proteins, Chem.-A Eur. J., 26, 4645, 10.1002/chem.201904568 · DOI
  54. Greineder, 2020, Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood–brain barrier, Proc. Natl. Acad. Sci. USA, 117, 3405, 10.1073/pnas.1912012117 · DOI
  55. Orleth, 2016, Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy, J. Drug Target., 24, 80, 10.3109/1061186X.2015.1056189 · DOI
  56. Loureiro, 2015, Dual ligand immunoliposomes for drug delivery to the brain, Colloids Surf. B Biointerfaces, 134, 213, 10.1016/j.colsurfb.2015.06.067 · DOI
  57. Paul, 2017, Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor, Am. J. Obstet. Gynecol., 216, e1, 10.1016/j.ajog.2016.08.027 · DOI
  58. Moles, 2015, Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy, J. Control. Release, 210, 217, 10.1016/j.jconrel.2015.05.284 · DOI
  59. Ramana, 2015, Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV, Eur. J. Pharm. Biopharm., 89, 300, 10.1016/j.ejpb.2014.11.021 · DOI
  60. Ding, 2020, Natural IgM dominates in vivo performance of liposomes, J. Control. Release, 319, 371, 10.1016/j.jconrel.2020.01.018 · DOI
  61. Rabenhold, 2015, Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously, J. Control. Release, 201, 56, 10.1016/j.jconrel.2015.01.022 · DOI
  62. Peng, 2019, Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer, Biomaterials, 222, 119420, 10.1016/j.biomaterials.2019.119420 · DOI
  63. Kraft, 2014, Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems, J. Pharm. Sci., 103, 29, 10.1002/jps.23773 · DOI
  64. Immordino, 2006, Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomed., 1, 297
  65. Scherphof, 1985, Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro, Ann. N. Y. Acad. Sci., 446, 368, 10.1111/j.1749-6632.1985.tb18414.x · DOI
  66. Cullis, 1998, Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo, Adv. Drug Deliv. Rev., 32, 3, 10.1016/S0169-409X(97)00128-2 · DOI
  67. Senior, 1991, Interaction of positively-charged liposomes with blood: Implications for their application in vivo, Biochim. Biophys. Acta, 1070, 173, 10.1016/0005-2736(91)90160-A · DOI
  68. Oku, 1996, Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography, Biochim. Biophys. Acta, 1280, 149, 10.1016/0005-2736(95)00283-9 · DOI
  69. Philippot, J.R., and Schube, F. (1994). Liposomes as Tools in Basic Research and Industry, CRC Press. [1st ed.].
  70. Du, 1997, Grafted poly-(ethylene glycol) on lipid surfaces inhibits protein adsorption and cell adhesion, Biochim. Biophys. Acta, 1326, 236, 10.1016/S0005-2736(97)00027-8 · DOI
  71. Hong, 1999, Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial?, Clin. Cancer Res., 5, 3645
  72. Parr, 1997, Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: The lack of beneficial effects by coating liposomes with poly(ethylene-glycol), J. Pharmacol. Exp. Ther., 280, 1319
  73. Kale, 2007, Design, Synthesis, and Characterization of pH-Sensitive PEG−PE Conjugates for Stimuli-Sensitive Pharmaceutical Nanocarriers: The Effect of Substitutes at the Hydrazone Linkage on the pH Stability of PEG−PE Conjugates, Bioconjugate Chem., 18, 363, 10.1021/bc060228x · DOI
  74. Sharma, 2019, Hypoxia-targeted drug delivery, Chem. Soc. Rev., 48, 771, 10.1039/C8CS00304A · DOI
  75. Andresen, 2010, Enzyme-triggered nanomedicine: Drug release strategies in cancer therapy (Invited Review), Mol. Membr. Biol., 27, 353, 10.3109/09687688.2010.515950 · DOI
  76. Li, 2019, Peptide-modulated self-assembly as a versatile strategy for tumor supramolecular nanotheranostics, Theranostics, 9, 3249, 10.7150/thno.31814 · DOI
  77. Horsman, 2016, Pathophysiological Basis for the Formation of the Tumor Microenvironment, Front. Oncol., 6, 1, 10.3389/fonc.2016.00066 · DOI
  78. Kalafatovic, 2016, MMP-9 triggered self-assembly of doxorubicin nanofiber depots halts tumor growth, Biomaterials, 98, 192, 10.1016/j.biomaterials.2016.04.039 · DOI
  79. Zhang, 2016, Multitriggered Tumor-Responsive Drug Delivery Vehicles Based on Protein and Polypeptide Coassembly for Enhanced Photodynamic Tumor Ablation, Small, 12, 5936, 10.1002/smll.201602339 · DOI
  80. Canavese, 2018, Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer, Chem. Eng. J., 340, 155, 10.1016/j.cej.2018.01.060 · DOI
  81. Sirsi, 2014, State-of-the-art materials for ultrasound-triggered drug delivery, Adv. Drug Deliv. Rev., 72, 3, 10.1016/j.addr.2013.12.010 · DOI
  82. VanOsdol, 2017, Sequential HIFU heating and nanobubble encapsulation provide efficient drug penetration from stealth and temperature sensitive liposomes in colon cancer, J. Control. Release, 247, 55, 10.1016/j.jconrel.2016.12.033 · DOI
  83. Huang, 2004, Acoustically active liposomes for drug encapsulation and ultrasound-triggered release, Biochim. Biophys. Acta, 1665, 134, 10.1016/j.bbamem.2004.07.003 · DOI
  84. Rapoport, 2004, Combined cancer therapy by micellar-encapsulated drug and ultrasound, Int. J. Pharm., 277, 155, 10.1016/j.ijpharm.2003.09.048 · DOI
  85. Leung, 2012, Light-Activated Content Release from Liposomes, Theranostics, 2, 1020, 10.7150/thno.4847 · DOI
  86. Pidgeon, 1983, Light sensitive liposomes, Photochem. Photobiol., 37, 491, 10.1111/j.1751-1097.1983.tb04506.x · DOI
  87. Ohya, 1998, Photo-sensitive lipid membrane perturbation by a single chain lipid having terminal spiropyran group, Supramol. Chem., 5, 21, 10.1016/S0968-5677(97)00070-9 · DOI
  88. Anderson, 1992, Triggered release of hydrophilic agents from plasmalogen liposomes using visible light or acid, Biochim. Biophys. Acta, 1109, 33, 10.1016/0005-2736(92)90183-M · DOI
  89. Thompson, 1996, Triggerable plasmalogen liposomes: Improvement of system efficiency, Biochim. Biophys. Acta, 1279, 25, 10.1016/0005-2736(95)00210-3 · DOI
  90. Wan, 2002, Liposomes from Novel Photolabile Phospholipids: Light-Induced Unloading of Small Molecules as Monitored by PFG NMR, J. Am. Chem. Soc., 124, 5610, 10.1021/ja016874i · DOI
  91. Li, 2003, Dithiane-based photolabile amphiphiles: Toward photolabile liposomes, Langmuir, 19, 6381, 10.1021/la034188m · DOI
  92. Zhang, 1999, Synthesis and Characterization of NVOC-DOPE, a Caged Photoactivatable Derivative of Dioleoylphosphatidylethanolamine, Bioconjugate Chem., 10, 1150, 10.1021/bc990087h · DOI
  93. Bayer, 2014, Triggered liposomal release through a synthetic phosphatidylcholine analogue bearing a photocleavable moiety embedded within the sn-2 acyl chain, Chemistry, 20, 3350, 10.1002/chem.201304094 · DOI
  94. Armitage, 1998, Polymerization of Preformed Self-Organized Assemblies, Acc. Chem. Res., 31, 861, 10.1021/ar970140m · DOI
  95. Yavlovich, 2011, A novel class of photo-triggerable liposomes containing DPPC:DC8,9PC as vehicles for delivery of doxorubcin to cells, Biochim. Biophys. Acta Biomembr., 1808, 117, 10.1016/j.bbamem.2010.07.030 · DOI
  96. Gerasimov, 1999, Cytosolic drug delivery using pH- and light-sensitive liposomes, Adv. Drug Deliv. Rev., 38, 317, 10.1016/S0169-409X(99)00035-6 · DOI
  97. Fuse, 2018, Effective light-triggered contents release from helper lipid-incorporated liposomes co-encapsulating gemcitabine and a water-soluble photosensitizer, Int. J. Pharm., 540, 50, 10.1016/j.ijpharm.2018.01.040 · DOI
  98. Li, 2018, A photosensitive liposome with NIR light triggered doxorubicin release as a combined photodynamic-chemo therapy system, J. Control. Release, 277, 114, 10.1016/j.jconrel.2018.02.001 · DOI
  99. Yatvin, 1978, Design of liposomes for enhanced local release of drugs by hyperthermia, Science, 202, 1290, 10.1126/science.364652 · DOI
  100. Ta, 2013, Thermosensitive liposomes for localized delivery and triggered release of chemotherapy, J. Control. Release, 169, 112, 10.1016/j.jconrel.2013.03.036 · DOI
  101. Nibu, 1995, Effect of headgroup type on the miscibility of homologous phospholipids with different acyl chain lengths in hydrated bilayer, Biophys. Chem., 56, 273, 10.1016/0301-4622(95)00041-U · DOI
  102. Meshorer, 1983, The effects of hyperthermia on normal mesenchymal tissues. Application of a histologic grading system, Arch. Pathol. Lab. Med., 107, 328
  103. Anyarambhatla, 1999, Enhancement of the Phase Transition Permeability of DPPC Liposomes by Incorporation of MPPC: A New Temperature-Sensitive Liposome for use with Mild Hyperthermia, J. Liposome Res., 9, 491, 10.3109/08982109909035549 · DOI
  104. Banno, 2010, The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo, J. Pharm. Sci., 99, 2295, 10.1002/jps.21988 · DOI
  105. Ickenstein, 2005, Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes, J. Control. Release, 107, 131, 10.1016/j.jconrel.2005.06.001 · DOI
  106. Swenson, C.E., Haemmerich, D., Maul, D.H., Knox, B., Ehrhart, N., and Reed, R.A. (2015). Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model. PLoS ONE, 10. · DOI
  107. Cicmanec, 2002, AC-magnetic field controlled drug release from magnetoliposomes: Design of a method for site-specific chemotherapy, Bioelectrochemistry, 55, 17, 10.1016/S1567-5394(01)00171-2 · DOI
  108. Nobuto, 2004, Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet, Int. J. Cancer, 109, 627, 10.1002/ijc.20035 · DOI
  109. Kubo, 2001, Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters, Int. J. Oncol., 18, 121
  110. Lampert, 2000, Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field, Z. Naturforsch. C J. Biosci., 55, 278, 10.1515/znc-2000-3-422 · DOI
  111. Matsunaga, 1997, Drug delivery by magnetoliposomes containing bacterial magnetic particles, Cell Eng., 2, 7
  112. Jain, 2003, RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting, Int. J. Pharm., 261, 43, 10.1016/S0378-5173(03)00269-2 · DOI
  113. Smith, 2016, Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment, J. Oncol. Pharm. Pract., 22, 599, 10.1177/1078155215594415 · DOI
  114. Bekersky, 2002, Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans, Antimicrob. Agents Chemother., 46, 828, 10.1128/AAC.46.3.828-833.2002 · DOI
  115. Charrois, 2004, Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer, Biochim. Biophys. Acta, 1663, 167, 10.1016/j.bbamem.2004.03.006 · DOI
  116. Boswell, 1998, AmBisome (liposomal amphotericin B): A comparative review, J. Clin. Pharmacol., 38, 583, 10.1002/j.1552-4604.1998.tb04464.x · DOI
  117. Walsh, 1998, Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients, Antimicrob. Agents Chemother., 42, 2391, 10.1128/AAC.42.9.2391 · DOI
  118. Paolo, 2011, Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase with Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma, Mol. Ther., 19, 2201, 10.1038/mt.2011.142 · DOI
  119. Cui, 2007, Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?, J. Control. Release, 118, 204, 10.1016/j.jconrel.2006.12.002 · DOI
  120. Cheung, 1998, Loading of doxorubicin into liposomes by forming Mn2+-drug complexes, Biochim. Biophys. Acta Biomembr., 1414, 205, 10.1016/S0005-2736(98)00168-0 · DOI
  121. Szebeni, 2015, Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs, Biochem. Biphys. Res. Commun., 468, 490, 10.1016/j.bbrc.2015.06.177 · DOI
  122. Szebeni, 2015, Hypersensitivity to intravenous iron: Classification, terminology, mechanisms and management, Br. J. Pharmacol., 172, 5025, 10.1111/bph.13268 · DOI
  123. Dobrovolskaia, 2016, Case Study: Complement Activation Related Hypersensitivity Reactions to PEGylated Liposomal Doxorubicin—Experimental and Clinical Evidence, Mechanisms and Approaches to Inhibition, Handbook of Immunological Properties of Engineered Nanomaterials, Volume 2, 331
  124. Kelly, 2015, High-throughput methods for screening liposome-macrophage cell interaction, J. Liposome Res., 25, 211, 10.3109/08982104.2014.987785 · DOI
  125. Wientjes, 2014, Predicting diffusive transport of cationic liposomes in 3-dimensional tumor spheroids, J. Control. Release, 192, 10, 10.1016/j.jconrel.2014.06.050 · DOI

Cited by

Sorted by citations

See all 118

Metadata

Authors
Gyanani, V., Haley, J. C., & Goswami, R.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2021-08-24
Volume
14
Issue
9
Pages
835
ISSN
1424-8247
DOI
10.3390/ph14090835
PMC
PMC8466509
Cited by
118
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review